Photrexa cross-linking kit 6ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCRW3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,337
Award facts
- Contract value 100% obligated
- $15,337.25 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $15,337.25 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Photrexa Cross-Linking Kit 6ML. The delivery order, awarded on January 23, 2026, with an ultimate completion date of February 13, 2026, carries no set-aside designation, indicating the vendor competed in an unrestricted procurement process. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract vehicle established on November 13, 2025, designed to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
The PPV-G GEN V program represents a component of the Defense Logistics Agency's broader $30.3 billion acquisition strategy to consolidate pharmaceutical procurement across multiple regional prime vendor contractors. Under this contract framework, DMS Pharmaceutical Group supplies an extensive portfolio of branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support recurring military healthcare operations. The company's demonstrated performance across numerous delivery orders, combined with its established federal contracting presence since 2001, positions it as a critical supplier within the Department of Defense's pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FCRW3?
SPE2DR26FCRW3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 23, 2026.
How much is contract SPE2DR26FCRW3 worth?
The government has obligated $15,337 on SPE2DR26FCRW3.
Is contract SPE2DR26FCRW3 an order under another contract?
Yes. SPE2DR26FCRW3 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRW3 competed?
The extent of competition for SPE2DR26FCRW3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award